Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityMinority InterestNon-Current AssetsOperating LeasesOther Non-Current AssetsPayablesPensionPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

MoonLake Immunotherapeutics (MLTX) Liabilities and Shareholders Equity (2020 - 2026)

MoonLake Immunotherapeutics' Liabilities and Shareholders Equity history spans 7 years, with the latest figure at $400.4 million for Q1 2026.

  • Quarterly Liabilities and Shareholders Equity fell 21.69% to $400.4 million in Q1 2026 from the year-ago period, while the trailing twelve-month figure was $1.7 billion through Mar 2026, down 17.2% year-over-year, with the annual reading at $424.4 million for FY2025, 11.19% down from the prior year.
  • Liabilities and Shareholders Equity came in at $400.4 million for Q1 2026, down from $424.4 million in the prior quarter.
  • In the past five years, Liabilities and Shareholders Equity ranged from a high of $564.1 million in Q1 2024 to a low of $66.8 million in Q1 2023.
  • The 5-year median for Liabilities and Shareholders Equity is $460.1 million (2025), against an average of $377.1 million.
  • Year-over-year, Liabilities and Shareholders Equity crashed 71.11% in 2023 and then skyrocketed 744.53% in 2024.
  • MoonLake Immunotherapeutics' Liabilities and Shareholders Equity stood at $76.8 million in 2022, then soared by 585.21% to $526.5 million in 2023, then decreased by 9.23% to $477.9 million in 2024, then fell by 11.19% to $424.4 million in 2025, then fell by 5.67% to $400.4 million in 2026.
  • Per Business Quant, the three most recent readings for MLTX's Liabilities and Shareholders Equity are $400.4 million (Q1 2026), $424.4 million (Q4 2025), and $414.3 million (Q3 2025).